Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

NCT00943501 · Completed

Last updated 2026-05-28

This clinical trial tested the safety of the medication liraglutide in children and adolescents with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 21 people

Who can join Ages 10–17 · all sexes

Timeline Started 2009-11 · est. completion 2011-09

Where 20 sites · Belgium, Slovenia, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT00943501 ↗

Description as written by the study sponsor.

This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered medication in blood over time) and pharmacodynamics (the determination of the effect over time and the duration of action) of multiple doses of liraglutide in the pediatric population (children).

Treatments tested

liraglutide Drug

Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
placebo Drug

Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
liraglutide Drug

Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
placebo Drug

Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).

Main thing measured	Number and type of adverse events
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00943501 ↗